2026 Artemetrx State of Specialty Spend and Trend Report
PSG announces the results of the industry’s go-to report on specialty drug spend and trend. With specialty drug costs remaining a top concern…
Read Post
Insights
Categories
Topics
Categories
Topics
Pharmaceutical Strategies Group Expands Artemetrx Solutions with Key Addition
DALLAS, TX – December 12, 2024 – Pharmaceutical Strategies Group (“PSG”), an EPIC company, announces the appointment of Travis Baughn as Vice President…
Read Post
Kebilidi: A Groundbreaking Gene Therapy Offering Hope for Rare Neurodevelopmental Disorder
The US Food and Drug Administration (FDA) approved the latest multimillion gene therapy. On November 13, 2024, the FDA approved Kebilidi (eladocagene exuparvovec-tneq), a…
Read Post
Pharmacy Benefits Research Unwrapped: Key Trends and Insights from 2024
Independent Pharmacy Benefit Research Helps Move the Industry Forward For over 30 years, PSG has been a trusted independent voice in pharmacy benefits management.
Read Post
GLP-1s for All: Biden And HHS Are Serving Up A Leaner America With The Latest Proposed Rule…And Much More
CMS Announcement Regarding GLP-1s Could Have Large Repercussions For Payers On November 26th, the Centers for Medicare and Medicaid Services (CMS) and the Biden…
Read Post
Living Our Values: PSG’s Commitment to Community Service
PSG’s Culture of Service Extends Beyond Its Clients When an EF3 tornado tore through Celina, Texas, last May, impacting hundreds in the area, the…
Read Post
Optimizing PBM Partnerships: Employer Strategies from PSG’s 2024 PBM Customer Satisfaction Report
Understanding Employer PBM Partnerships Allows for Improved Pharmacy Benefit Strategy After analyzing responses from nearly 250 healthcare payers, PSG recently published the 2024…
Read Post
2025 Formulary Changes: Big 3 PBMs
PBMs have announced the changes to their formulary for the year 2025, which will take effect 1/1/2025. In light of these changes, PSG has…
Read Post
2025 Formulary Changes: CVS Caremark
Get the Full Analysis of other Formulary Changes: Express Scripts Optum Rx The following is an…
Read Post
2025 Formulary Changes: Optum Rx
Get the Full Analysis of other Formulary Changes: CVS Caremark Express Scripts The following is an…
Read Post
How Health Plans and Employers Can Prepare for New and Upcoming Gene Therapies
Two gene therapies, Casgevy and Lyfgenia, were approved late last year by the FDA for treating Sickle Cell Disease (SCD). SCD is a debilitating…
Read Post
2025 Formulary Changes: Express Scripts
Get the Full Analysis of other Formulary Changes: CVS Caremark Optum Rx The following is an…
Read Post